US FDA grants approval for AstraZeneca’s lung cancer therapy
Pharmaceutical Technology
NOVEMBER 13, 2022
The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) and platinum-based chemotherapy to treat Stage IV (metastatic) non-small cell lung cancer (NSCLC) in adults. The approval was based on the findings from the randomised, multicentre, open-label, international Phase III POSEIDON trial.
Let's personalize your content